Overview

  • Product nameAnti-Tau antibodySee all Tau primary antibodies ...
  • Description
    Chicken polyclonal to Tau
  • Tested applicationsWB, IHC-P, ICC more details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Two synthetic peptides corresponding to two regions of the Tau gene product corresponding to sequences shared between the mouse (P01637, NCBI) and human (NP_05819, NCBI) proteins, and not containing any of the serine and threonine residues known to undergo phosphorylation.

  • Positive control
    • Hippocampus neurons of a patient with Alzheimer's disease. This antibody gave a positive result in IHC in the following FFPE tissue: Human Hippocampus (Alzheimer's).
  • General notes


    Two different affinity purified anti peptide antibodies were combined to make this product. The concentrations of both of these antibodies was 100 µg/ml, making the total antibody concentration 200 µg/ml.

Properties

Applications

Our Abpromise guarantee covers the use of ab75714 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB 1/20000 - 1/50000. Predicted molecular weight: 79 kDa.
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC 1/1000 - 1/2000.

Target

  • FunctionPromotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
  • Tissue specificityExpressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
  • Involvement in diseaseNote=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
    Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
    Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
    Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
    Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
  • Sequence similaritiesContains 4 Tau/MAP repeats.
  • Developmental stageFour-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
  • DomainThe tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
  • Post-translational
    modifications
    Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
    Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
    Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
  • Cellular localizationCytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
  • Target information above from: UniProt accession P10636 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • FormThere are 9 isoforms produced by alternative splicing.
  • Alternative names
    • AI413597 antibody
    • AW045860 antibody
    • DDPAC antibody
    • Disinhibition dementia parkinsonism amyotrophy complex antibody
    • FLJ31424 antibody
    • FTDP 17 antibody
    • FTDP17 antibody
    • G Protein beta 1 gamma 2 subunit interacting factor 1 antibody
    • G protein beta1/gamma2 subunit interacting factor 1 antibody
    • MAPT antibody
    • MAPTL antibody
    • MGC134287 antibody
    • MGC138549 antibody
    • MGC156663 antibody
    • Microtubule associated protein tau antibody
    • Microtubule associated protein tau isoform 4 antibody
    • Microtubule associated protein tau, isoform 4 antibody
    • Microtubule-associated protein tau antibody
    • MSTD antibody
    • MTAPT antibody
    • MTBT 1 antibody
    • MTBT 2 antibody
    • MTBT1 antibody
    • MTBT2 antibody
    • Neurofibrillary tangle protein antibody
    • Paired helical filament tau antibody
    • Paired helical filament-tau antibody
    • PHF tau antibody
    • PHF-tau antibody
    • PPND antibody
    • pTau antibody
    • RNPTAU antibody
    • TAU antibody
    • TAU_HUMAN antibody
    • Tauopathy and respiratory failure, included antibody
    see all

Anti-Tau antibody images

  • IHC image of Tau staining in Human Hippocampus (Alzheimer's) (ab4583) formalin-fixed paraffin-embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab75714, 5 µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

     

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

  • ab75714 staining Tau in rat hippocampal neurons by Immunocytochemistry/ Immunofluorescence.
    Cells were fixed in paraformaldehyde, permeabilized using 0.25% Triton, blocked with 3% BSA for 30 minutes at room temperature and then incubated with ab75714 at a 1/1000 dilution for 16 hours at 4°C. The secondary used was an Alexa-Fluor 488 conjugated goat anti-chicken polyclonal used at a 1/1000 dilution.

    Staining in rat neurons is great. Hippocampal cultured neurons (DIV7) were labelled against tau (green), tubulin (red) and DAPI (blue).

    See Abreview

  • Immunofluorescence analysis of primary entorhinal cortex neurons prepared from five-day-old rats, staining Tau with ab75714 at 1/1500 dilution.

    Cells were fixed with paraformaldehyde, blocked in PBS + 5% fetal calf serum (ab7479), then permeabilized in PBS containing 0.2% Triton X-100. Samples were incubated with primary antibody for 2 hours at room temperature. A Cy5®-conjugated anti-chicken IgG was used as the secondary antibody.

References for Anti-Tau antibody (ab75714)

This product has been referenced in:
  • Wilkars W  et al. Regulation of axonal HCN1 trafficking in perforant path involves expression of specific TRIP8b isoforms. PLoS One 7:e32181 (2012). ICC/IF ; Rat . Read more (PubMed: 22363812) »

See 1 Publication for this product

Product Wall

This is confusing. ab113316 is a kit not antibody, customer would not be requiring a DAB kit for this.

For ab101854, ab80436 will be a good product.

Thanks!

Thank you for contacting us.

The kits ab80436 and ab64264, both will be OK to use with ab10148 only because it is rabbit antibody, you can select any one of them. Please note that these kits cannot be used with ab75714 because it is a chicken ...

Read More

Thank you for contacting us.

The Tau antibody was raised against two distinct peptides corresponding to identical sequences shared in the mouse and human gene product.



These peptides are located in the C-terminal third of th...

Read More

Thank you very much for your interest in ab75714.
To our knowledge, ab75714 has not been tested in Zebrafish. Therefore, I can offer a discount off a future purchase if you buy ab75714 now, test it in Zebrafish and submit feedback to us in the form...

Read More

Thank you for your inquiry.


For ab58201, we have 2 customer submitted Abreviews showing the antibody working in immunocytochemistry (ICC/IF), onewith rat glioma cells and the other with human glioblastoma cells. However, we don't have a...

Read More
Application Immunocytochemistry
Sample Rat Cultured Cells (hippocampal neurons)
Specification hippocampal neurons
Fixative Paraformaldehyde
Permeabilization Yes - triton 0,25%
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 3% · Temperature: RT°C
Username

Maria Joana

Verified customer

Submitted Jan 04 2012

Thank you for your enquiry. Rest assured that there is NO BSA nor glycerol in this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"